Joseph Zimmermann is the President and CEO of Biodextris, a contract development organization that spun out of GSK Vaccines in May, 2015. Previously, Joseph was the Director of New Product Development at GSK Vaccines since 2005, overseeing a group of 35-40 process development and analytical scientists. Joseph also was the Project Leader for two early phase development products; intranasal influenza and transdermal vaccine delivery, and led an internal company-wide initiative to evaluate and shorten development timelines. Prior to GSK, Joseph was the Project Leader for ID Biomedical’s Flu development program. He joined ID Biomedical in 2002, to help establish the company’s biodefense program which received more than 30 million USD in funding and contracts. Joseph started his career at Ibex Technologies (Montreal) where he was Vice-President of Research and Development. Under his direction Ibex developed three hematology diagnostic products which are still in the market. He also led the process and clinical development of the company’s lead product, Neutralase, through Phase II clinical trials and initiated an orphan drug – enzyme replacement program. Joseph worked as a Regulatory Affairs consultant for Clementi & Associates (Philadelphia) from 1997-2000. Joseph received a PhD in Biochemical Engineering from MIT in 1988, a M.Phil in Pharmacology from the University of Cambridge in 1981 and a BS in Chemical Engineering from Columbia University in 1980. Joseph is an author of 25 reviewed publications and 15 issued patents.